SHIFT IN CUSTOMER DYNAMICS FUELING FUTURE-FORWARD BUSINESS GROWTH

Considering India’s ‘Pharmacy of the World’ stature, what are the primary drivers propelling its pharmaceutical industry, and how has Lupin specifically contributed to this global prominence?

- RAJEEV SIBAL President - India Region Formulations, Lupin Limited

India’s stature as the ‘Pharmacy of the World’ is driven by its unmatched capability in manufacturing high-quality, affordable medicines at scale. This growth is supported by our strong expertise in generics, a robust manufacturing ecosystem that adheres to global regulatory standards, deep scientific and R&D talent, and a resilient supply chain. These features have positioned India as the largest supplier of generics globally and a prominent exporter of vaccines and essential pharmaceuticals.

With 15 manufacturing plants and 7 research facilities, Lupin has consistently contributed to this journey. We have a strong presence in India, North America, EMEA, and APAC, offering products in over 100 countries. Lupin's leadership in cardiovascular, respiratory, and diabetes therapies and pioneering work in complex generics and biosimilars has helped strengthen India’s global pharmaceutical presence. Beyond products, our consistent focus on quality, patient-centric innovation, and partnerships across geographies to provide quality medicines and expand access while delivering on the promise of affordable healthcare worldwide. In doing so, Lupin continues to play an integral role in reinforcing India’s reputation as a trusted healthcare partner to the world.

The total market size of the Indian Pharma Industry is expected to reach US$ 130 billion by 2030 and US$ 450 billion market by 2047. According to you, what have been the key achievements of the industry to support these projections?